Online inquiry

IVTScrip™ pT7-VEE-mRNA-TGFB1 Vector   (CAT#: GTVCR-WQ0010MR)

The vector is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate TGFB1 mRNA through T7 RNA polymerase and nucleotides under appropriate reaction conditions. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
5' UTR Kozak seq
Resistance Ampicillin
Species Human
RefSeq NM_000660.7
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 7040
UniProt ID P01137
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-TGFB1 Vector (GTVCR-WQ0010MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ871MR IVTScrip™ pT7-VEE-mRNA-Anti-IL13, CAT-354 Vector Vector CAT-354
GTVCR-WQ804MR IVTScrip™ pT7-VEE-mRNA-Anti-TNFSF13B, BR3-Fc Vector Vector BR3-Fc
GTVCR-WQ547MR IVTScrip™ pT7-VEE-mRNA-Anti-FCGRT, ARGX-113 Vector Vector ARGX-113
GTVCR-WQ543MR IVTScrip™ pT7-VEE-mRNA-Anti-CD70, ARGX-110 Vector Vector ARGX-110
GTVCR-WQ898MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1) Vector Vector CD20-TCB (2:1)
GTVCR-WQ2310MR IVTScrip™ pSP6-VEE-mRNA-Anti-S, REGN-10933 Vector Vector REGN-10933
GTVCR-WQ1438MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD47, Hu5F9-G4 Vector Vector Hu5F9-G4
GTVCR-WQ814MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD4, BT-061 Vector Vector BT-061
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW